Soluble EP2 neutralizes prostaglandin E2-induced cell signaling and inhibits osteolytic tumor growth

Molecular Cancer Therapeutics

Volumn 7, Issue 9, 2008, Pages 2807-2816

  Takahashi, Tetsuyuki ^a   Uehara, Hisanori ^a   Bando, Yoshimi ^a   Izumi, Keisuke ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYCLIC AMP; CYCLOOXYGENASE 2; E PROSTANOID RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; PROSTAGLANDIN E2; PROSTANOID RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BONE METASTASIS; CANCER CELL; CANCER GROWTH; CULTURE MEDIUM; EMBRYO; ENZYME INDUCTION; EXPRESSION VECTOR; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUDE MOUSE; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; VECTOR CONTROL;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; CYCLOOXYGENASE 2; DINOPROSTONE; DOWN-REGULATION; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MICE; MICE, NUDE; NEOPLASMS; OSTEOCLASTS; OSTEOLYSIS; PEPTIDE FRAGMENTS; RECEPTORS, PROSTAGLANDIN E; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; SIGNAL TRANSDUCTION; SOLUBILITY; TIBIA;

EID: 54049104058     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0153     Document Type: Article

References (40)

1. Wang D, Dubois RN. Prostaglandins and cancer. Gut 2006;55:115-22.
2. Ono K, Akatsu T, Murakami T, et al. Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines. J Bone Miner Res 2002;17:774-81.
3. Gamradt SC, Feeley BT, Liu NQ, et al. The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone. Anticancer Res 2005;25:107-15.
4. Singh B, Berry JA, Shoher A, Ayers GD, Wei C, Lucci A. COX-2 involvement in breast cancer metastasis to bone. Oncogene 2007;26:3789-96.
5. Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994;46:205-29.
6. Funk CD, Furci L, FitzGerald GA, et al. Cloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype. J Biol Chem 1993;268:26767-72.
7. 2 receptor EP2 subtype. J Biol Chem 1994;269:11873-7.
8. Namba T, Sugimoto Y, Negishi M, et al. Alternative splicing of C-terminal tail of prostaglandin E receptor subtype EP3 determines G-protein specificity. Nature 1993;365:166-70.
9. Regan JW, Bailey TJ, Pepperl DJ, et al. Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype. Mol Pharmacol 1994;46:213-20.
10. Siu YT, Jin DY. CREB-a real culprit in oncogenesis. FEBS J 2007;274:3224-32.
11. Watanabe K, Kawamori T, Nakatsugi S, et al. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res 1999;59:5093-6.
12. 4 in colon carcinogenesis. Cancer Res 2002;62:28-32.
13. Sonoshita M, Takaku K, Sasaki N, et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc (Δ716) knockout mice. Nat Med 2001;7:1048-51.
14. Kitamura T, Itoh M, Noda T, et al. Combined effects of prostaglandin E receptor subtype EP1 and subtype EP4 antagonists on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice. Cancer Sci 2003;94:618-21.
15. Niho N, Mutoh M, Kitamura T, et al. Suppression of azoxymethane-induced colon cancer development in rats by a prostaglandin E receptor EP1-selective antagonist. Cancer Sci 2005;96:260-4.
16. Yang L, Huang Y, Porta R, et al. Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. Cancer Res 2006;66:9665-72.
17. Ohshiba T, Miyaura C, Ito A. Role of prostaglandin E produced by osteoblasts in osteolysis due to bone metastasis. Biochem Biophys Res Commun 2003;300:957-64.
18. 2 signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/ receptor activator of nuclear factor-κB (RANK) ligand/RANK system. Endocrinology 2005;146:1991-8.
19. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998;188:997-1001.
20. 2 in prostaglandin E receptor EP4-knockout mice. J Biol Chem 2000;275:19819-23.
21. Sabino MA, Ghilardi JR, Jongen JL, et al. Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res 2002;62:7343-9.
22. Takita M, Inada M, Maruyama T, Miyaura C. Prostaglandin E receptor EP4 antagonist suppresses osteolysis due to bone metastasis of mouse malignant melanoma cells. FEBS Lett 2007;581:565-71.
23. 2 and the protein kinase A pathway mediate arachidonic acid induction of c-fos in human prostate cancer cells. Br J Cancer 2000;82:2000-6.
24. Uehara H, Kim SJ, Karashima T, et al. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 2003;95:558-70.
25. Stillman BA, Audoly L, Breyer RM. A conserved threonine in the second extracellular loop of the human EP2 and EP4 receptors is required for ligand binding. Eur J Pharmacol 1998;357:73-82.
26. 2, E-prostanoid 2 (EP2), and EP4 receptors. J Biol Chem 2003;278:49954-64.
27. Anasagasti MJ, Olaso E, Calvo F, et al. Interleukin 1-dependent and -independent mouse melanoma metastasis. J Natl Cancer Inst 1997;89:645-51.
28. Kurihara N, Bertolini D, Suda T, Akiyama Y, Roodman GD. IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J Immunol 1990;144:4226-30.
29. Inoue H, Yokoyama C, Hara S, Tone Y, Tanabe T. Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element. J Biol Chem 1995;270:24965-71.
30. Gray JG, Chandra G, Clay WC, et al. A CRE/ATF-like site in the upstream regulatory sequence of the human interleukin 1β gene us necessary for induction in U937 and THP-1 monocytic cell lines. Mol Cell Biol 1993;13:6678-89.
31. Ray A, Sassone-Corsi P, Sehgal PB. A multiple cytokine- and second messenger-responsive element in the enhancer of the human interleukin-6 gene: similarities with c-fos gene regulation. Mol Cell Biol 1989;9:5537-47.
32. DeAntoni EP, Crawford ED. Pretreatment of metastatic disease. Prostate cancer in the older male. Cancer 1994;74:2182-7.
33. Soos G, Jones RF, Haas GP, Wang CY. Comparative intraosseal growth of human prostate cancer cell lines LNCaP and PC-3 in the nude mouse. Anticancer Res 1997;17:4253-8.
34. 2. Adv Exp Med Biol 1997;407:163-70.
35. 2 in human colon cancer cells. Cancer Res 1998;58:362-6.
36. 2 dependent cell survival thorough the PI3 kinase/AKT pathway. Prostaglandins Other Lipid Mediat 2007;83:112-20.
37. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002;360:1071-3.
38. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709-11.
39. 2α-FP receptor interaction in human endometrial adenocarcinomas. Cancer Res 2005;65:7707-16.
40. 2α stimulates motility and invasion in colorectal tumor cells. Int J Cancer 2007;121:734-40.